DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/98067f/belarus_pharmaceut) has announced the addition of the "Belarus Pharmaceuticals and Healthcare Report Q2 2011" report to their offering.
Belarus has a potentially attractive pharmaceutical market and ideal geographic placement to access both European Union markets and the largest CIS markets of Russia and Ukraine. In reality, however, the country's high degree of state economic management and the pariah status of its senior leadership following a brutal election crackdown in late 2010 has deterred most direct foreign investment in the pharma sector. The Customs Union with Russia and Kazakhstan means in practice that foreign companies will prefer to invest in Russia and export to Belarus to lessen their risk exposure. Current state policy foresees a multifold increase in pharmaceutical exports over five years, a policy even the central bank chief has questioned.
Headline Expenditure Projections:
- Pharmaceuticals: BYR2,111bn (US$720mn) in 2010 to BYR2,407bn (US$752mn) in 2011; +14.0% in local currency terms and +4.4% in US dollar terms. Forecast down moderately from Q111 due to macroeconomic factors and analyst modification of 2009 figures.
- Healthcare: BYR11,964bn (US$4.1bn) in 2010 to BYR14,002bn (US$4.4bn) in 2011; +17.0% in local currency terms and +7.2% in US dollar terms. Forecast up due macroeconomic factors from Q111.
- Medical devices: BYR778.1bn (US$265mn) in 2010 to BYR891.4bn (US$278mn) in 2011; +14.6% in local currency terms and +4.9% in US dollar terms. Forecast down marginally from Q111 due to analyst macroeconomic factors.
Business Environment Rating: Belarus's score was slashed from 48.2 in Q211 to 40.7 in Q111, a result of a 12-point decline in industry rewards in view of the country's deteriorating overall business climate, increased government intervention in the economy and alternative for companies to import into the country from within the Customs Union. The country's ranking in the Central and Eastern European coverage universe declined from 12th to 18th out of 20 in one quarter, largely the result of the country's bloody post-election crackdown and consequent political and economic fallout.
Prime Minister Mikhail Myasnikovich claimed the country would build sophisticated turn-key new pharmaceutical plants in cooperation with global brands over the next five years in a speech covering the government's economic development plans in March. Strikingly, the country's national bank head questioned calls for a four-fold increase in exports by state-owned Belbiopharm as unrealistic.
Companies Mentioned:
- Belbiopharm
- Lekpharm
For more information on this report visit http://www.researchandmarkets.com/research/98067f/belarus_pharmaceut